Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.

Wolfgang Peter Fendler Kim Magaly Pabst Lukas Kessler Pedro Fragoso Costa Justin Ferdinandus Manuel Weber Maria Lippert Katharina Lückerath Lale Umutlu Karina Kostbade Ilektra A Mavroeidi Martin Schuler Marit Ahrens Christoph Rischpler Sebastian Bauer Ken Herrmann Jens Thomas Siveke Rainer Hamacher

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

90Y-FAPI-46-RLT was safe and led to RECIST PR in one case as well as stable disease in about one third of patients with initially progressive sarcomas, pancreatic cancer, and other cancers. Discontinuation after the first cycle and a low rate of PR requires future improvement of FAP-RLT.

Keyphrases

papillary thyroid
multiple sclerosis
squamous cell
current status
high grade
childhood cancer
lymph node metastasis
bone marrow
mesenchymal stem cells
cell therapy